Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Travere Therapeutics, Inc.TVTX · Entity 1562 | CHIEF FINANCIAL OFFICER | September 15, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Travere Therapeutics, Inc.
Report date September 15, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 87,508 |
Ending reported balance
After 2026-09-15 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 20,000 · Balance 138,016 Row 2 · 2026-09-15 · Sale · Disposed 27,473 · Balance 110,543 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F2: The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 3 · 2026-09-15 · Sale · Disposed 20,735 · Balance 89,808 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F3: The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 4 · 2026-09-15 · Sale · Disposed 1,900 · Balance 87,908 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. F4: The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. Row 5 · 2026-09-15 · Sale · Disposed 400 · Balance 87,508 F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027. |
| Employee stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.44 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-09-15 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-15 · Exercise / conversion · Disposed 20,000 · Balance 0 F5: The stock option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made pursuant to a written plan adopted on June 16, 2026, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares underlying a stock option granted to the Reporting Person with an expiration date of May 17, 2027.
F2: The weighted average sale price for the transaction reported was $61.9969, and the range of prices were between $61.38 and $62.37. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $62.6079, and the range of prices were between $62.38 and $63.30. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: The weighted average sale price for the transaction reported was $63.6865, and the range of prices were between $63.59 and $63.86. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F5: The stock option is fully vested and exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2023 Filed Feb 3, 2023 00:02 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 20,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006422 · doc4.xml · nonDerivative · entry 1 Cline Christopher R. · CIK 0001943192 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,121 F1 · kind: Each restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:05 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | SaleCommon Stock | 852 | $21.90 | $18,662.55 |
DisclosureSEC source: 0001209191-23-005032 · doc4.xml · nonDerivative · entry 1 Cline Christopher R. · CIK 0001943192 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,871 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover the tax withholding obligation in connection with the settlement of vested restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a "sell to cover" transaction with a brokerage firm designated by the Issuer. This sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 22:20 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantPerformance-based restricted stock units · Derivative | 9,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048347 · doc4.xml · derivative · entry 3 Cline Christopher R. · CIK 0001943192 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,840 Underlying: Common Stock · 9,840 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Common Stock of the Issuer. F4 · derivative.exercise_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31,2027 to the extent the specified performance based milestones are not achieved by such date. F4 · derivative.expiration_date: This grant will vest upon the achievement of specified clinical/regulatory and commercial milestones, provided, however, if either vesting event occurs before the date that is 12 months after the date of grant, then the portion of the award that would have vested upon such event will instead vest on the date that is 12 months after the date of grant, and provided further that the Performance RSU will expire on January 31,2027 to the extent the specified performance based milestones are not achieved by such date. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 22:20 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantEmployee Stock option (right to buy) · Derivative | 48,000 | $0.00 Strike: $28.06 | $0.00 |
DisclosureSEC source: 0001209191-22-048347 · doc4.xml · derivative · entry 2 Cline Christopher R. · CIK 0001943192 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2032-08-31 F2 · derivative.exercise_date: One-fourth of the shares subject to the stock option vest and become exercisable on the first anniversary of the date of grant, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| September 01, 2022 Filed Sep 1, 2022 22:20 UTC | Travere Therapeutics, Inc. TVTX · Entity 1562 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048347 · doc4.xml · nonDerivative · entry 1 Cline Christopher R. · CIK 0001943192 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,723 F1 · shares: The equity award vests over four years, with 1/4th vesting on each anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.